FARA

Presentation Of "Lethal Injustice" Investigative Report To Congress And Members Of The Western Intelligence Community

Retrieved on: 
Monday, August 16, 2021
President Trump, Congress, Crime, Research, Atrocity, Family, Vaccination, Trump, Foreign Agent, FARA, HCIR, Foreign Agents Registration Act, MAGA, COVID-19, Drug

The report exposes the shift and friendliness of American conservatives towards Russia and their transformation into an agency of influence for Vladimir Putin.

Key Points: 
  • The report exposes the shift and friendliness of American conservatives towards Russia and their transformation into an agency of influence for Vladimir Putin.
  • Considering the urgent need for humane comprehensive immigration reform (HCIR), this report lays the foundation for Congress to investigate atrocities on the US-Mexico border by former President Trump and his family.
  • Media check-in at 9 a.m., opening remarks at 9:30 a.m.
    Limited in-person attendance.
  • Must have proof of vaccination or negative Covid19 test results.

Wilson Sonsini Expands National Security Regulatory Practice

Retrieved on: 
Monday, August 9, 2021
Aircraft, Foreign Agents Registration Act, Technology, Corruption, Compliance, Ethics & Compliance Initiative, Sikorsky Aircraft, International Traffic in Arms Regulations, Foreign Corrupt Practices Act, ITAR, George Washington University Law School, PALO, Government, Booz Allen Hamilton, Williams Mullen, Classification, FARA, List, Silicon, The Johns Hopkins University SAIS Europe, Applied Physics Laboratory, Multimedia, Private law, FCPA, PC, Ethics, National Industrial Chemicals Notification and Assessment Scheme, Foreign investment, Agent handling, ITC, Privacy, George Washington University, Wilson Sonsini Goodrich & Rosati, Committee, NISPOM, Research, DE, International trade, Committee on Foreign Investment in the United States, Public relations

She will be a member of Wilson Sonsini's national security practice.

Key Points: 
  • She will be a member of Wilson Sonsini's national security practice.
  • Prior to joining Wilson Sonsini, Hartwig served as a principal and associate general counsel for Ethics & Compliance at Booz Allen Hamilton, Inc.
  • Based in Washington, D.C., Wilson Sonsini's national security practice advises clients ranging from large multinational companies to small start-ups on national security issues, notably the Committee on Foreign Investment in the United States, technology transactions, export controls and economic sanctions, cyber security, corruption and bribery, and privacy and data protection.
  • The firm's attorneys have deep experience in the national security community and counsel clients on all aspects of national security issues, including advising on various government licensing requirements; assisting with obtaining required government authorizations; and representing clients throughout government inquiries and investigations, board investigations, mergers and acquisitions, and congressional inquiries.

Qatar-Based Travel Firm Mosafer, Inc. Files Lawsuit Against Elliott Broidy And George Nader In US Federal Court For Allegedly Illegally Orchestrating And Executing Secret Assault Against Qatar And Qatari Businesses; Suit Alleges They Violated Fara And Oth

Retrieved on: 
Friday, August 6, 2021
President Trump, District court, MENA, European Union, Independent agencies of the United States government, Ecosystem, Twitter, Press, Trump Victory Committee, Iron group, Union, United Arab Emirates, Trump, Republican National Committee, Non-governmental organization, BCM, Social media, Internet, Associated, News, The New York Times, Child, Agent handling, Thought, SAFE, White House, YouTube, RNC, Sex, The Washington Post, Tourism, Cerberus Capital Management, Assault, AMG Capital Management, LLC v. FTC, White, Government, Definers Public Affairs, Safety, Contract, FARA, AP, Defendant, LLC, SCL, Travel, Foreign Agents Registration Act, Ridesharing company, Online gambling, Cryptocurrency, Public relations, Risk management

The Mosafer brand had a presence in Qatar, Saudi Arabia, the United Arab Emirates, Jordan, Turkey, and South Africa.

Key Points: 
  • The Mosafer brand had a presence in Qatar, Saudi Arabia, the United Arab Emirates, Jordan, Turkey, and South Africa.
  • The lawsuit states, "As confirmed by prosecutors, Broidy's unregistered foreign lobbying efforts extended far beyond those that he pled guilty to.
  • Upon information and belief, these documents show that Broidy and Nader acted as unregistered agents of the UAE in violation of FARA."
  • 611 et seq., and other federal and state lawsBroidy and Nader orchestrated and implemented a vast, sophisticated campaign against Qatar and Qatari-based businesses.

Exicure, Inc. Reports Full Year 2020 Financial Results and Corporate Progress

Retrieved on: 
Thursday, March 11, 2021
Research, Genetics, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Health sciences, Health, Clinical research, Drug discovery, Pharmaceutical industry, Clinical trials, Friedreich’s Ataxia (FA), FARA, Exicure

As of February 23, 2021, 16 clinical sites were open for enrollment and 7 additional sites were pending activation.

Key Points: 
  • As of February 23, 2021, 16 clinical sites were open for enrollment and 7 additional sites were pending activation.
  • In June 2020, the Company reported the dosing of the first patient in the MCC cohort of the clinical trial.
  • In September 2020, Exicure reported that it had completed enrollment of the Phase 1b stage of the clinical trial for cavrotolimod (AST-008).
  • The COVID-19 pandemic or its impact or effects could have a material adverse impact on the Companys business, operations and financial results for an extended period of time.

Exicure, Inc. Reports Second Quarter 2020 Financial Results and Corporate Progress

Retrieved on: 
Wednesday, August 12, 2020
Research, Genetics, Clinical trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Spherical nucleic acid, NASDAQ, Cash and cash equivalents, Money, Finance, Economy, our Pipeline, FARA, Exicure, Inc.

Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today reported financial results for the quarter and six months ended June 30, 2020 and provided an update on corporate progress.

Key Points: 
  • Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today reported financial results for the quarter and six months ended June 30, 2020 and provided an update on corporate progress.
  • The second quarter was marked by important new expansion, said Dr. David Giljohann Exicures Chief Executive Officer.
  • Cash Position: Cash, cash equivalents, and short-term investments were $85.8 million as of June 30, 2020 as compared to $98.8 million as of March 31, 2020.
  • The COVID-19 pandemic could have a material adverse impact on the companys business, operations and financial results for an extended period of time.

Exicure, Inc. Reports First Quarter 2020 Financial Results and Corporate Progress

Retrieved on: 
Thursday, May 14, 2020
Research, Genetics, Clinical trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Spherical nucleic acid, FARA, Exicure, Inc.

Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today reported financial results for the quarter ended March 31, 2020 and provided an update on corporate progress.

Key Points: 
  • Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today reported financial results for the quarter ended March 31, 2020 and provided an update on corporate progress.
  • Research and Development (R&D) Expenses: Research and development expenses were $6.1 million for the quarter ended March 31, 2020, compared to $3.4 million for the quarter ended March 31, 2019.
  • General and Administrative (G&A) Expenses: General and administrative expenses were $2.6 million for the quarter ended March 31, 2020, compared to $2.2 million for the quarter ended March 31, 2019.
  • The COVID-19 pandemic could have a material adverse impact on the companys business, operations and financial results for an extended period of time.

Exicure, Inc. Reports Full Year 2019 Financial Results and Corporate Progress

Retrieved on: 
Tuesday, March 3, 2020
Oncology, Health, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Neurological disorders, Organ systems, Rare diseases, Frataxin, Proteins, Neurodegenerative disorders, Autosomal dominant disorders, Spinocerebellar ataxia, Ataxin, Ataxia, Cerebellar ataxia, Spherical nucleic acid, Friedreich’s Ataxia (FA), FARA, Exicure, Inc.

Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today reported full year financial results for year ended December 31, 2019 and provided an update on corporate progress.

Key Points: 
  • Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today reported full year financial results for year ended December 31, 2019 and provided an update on corporate progress.
  • FA is driven by triplet repeats in the frataxin gene which compromises the patients ability to generate adequate levels of frataxin protein.
  • Exicure is currently exploring additional neurological conditions, including spinocerebellar ataxia, Batten disease, amyotrophic lateral sclerosis (ALS), and Huntingtons disease.
  • In December of 2019, Exicure announced preliminary results from the Phase 1b study of AST-008 in patients with solid tumors.

 Exicure Announces First Neurological Development Program in Friedreich’s Ataxia and Expands Scientific Advisory Board

Retrieved on: 
Monday, December 16, 2019
Health, Genetics, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Neurological disorders, Rare diseases, Friedreich's Ataxia Research Alliance, Trinucleotide repeat disorders, Organ systems, Fara, Friedreich's ataxia, Ataxia, Nikolaus Friedreich, Kyle Bryant, Autosomal dominant disorders, Friedreich’s Ataxia (FA), FARA, Exicure, Inc.

Exicure also announced the expansion of its Scientific Advisory Board.

Key Points: 
  • Exicure also announced the expansion of its Scientific Advisory Board.
  • Over the past year Exicure has developed extensive preclinical data supporting the development of our SNAs for neurological disorders.
  • We are also pleased to add the experience and team from the Friedreichs Ataxia Research Alliance (FARA), added Dr. Giljohann.
  • The Friedreich's Ataxia Research Alliance (FARA) is a 501(c)(3), non-profit, charitable organization dedicated to accelerating research leading to treatments and a cure for Friedreich's ataxia.